

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ClouDr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9955)

VOLUNTARY ANNOUNCEMENT

EXPERT CONSENSUS ON ESTABLISHMENT AND APPLICATION OF

INTERNET HEALTHCARE-RELATED INTELLIGENCE ASSISTED

PRESCRIPTION REVIEW SYSTEM, LED BY THE CHINESE

SOCIETY OF CLINICAL PHARMACY OF THE CHINESE MEDICAL

ASSOCIATION AND OTHER PROFESSIONAL ASSOCIATIONS, AND

JOINTLY DEVELOPED AND PUBLISHED BY THE COMPANY AND

35 CLASS III-A HOSPITALS

This announcement is made by ClouDr Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform its shareholders and potential investors of the recent developments of the Group.

The Company is pleased to announce that the expert consensus on the “establishment and application of an Internet healthcare-related intelligence assisted prescription review system”, led by the Chinese Society of Clinical Pharmacy of the Chinese Medical Association, the Clinical Pharmacy Society of the Shanghai Medical Association, and the Hospital Pharmacy Committee of the Shanghai Medical Association, and jointly developed by the Company and 35 Class III-A hospitals across China, was officially released in Shanghai on 10 June 2023. The expert consensus on out-of-hospital intelligent processing and outflow of digital prescriptions after diagnosis and treatment is the first of its kind in the world and fills a gap in the country, with a view to guiding the standardised development of the digital healthcare industry.

Based on medical institutions' experience of establishing prescription review systems, the expert consensus represents suggestions on the establishment and application of an Internet healthcare-related intelligence assisted prescription review system, aiming to further promote the standardisation of Internet-based and digital medical diagnosis and treatment and prescription review, advocate the rational use of medicines, and ensure the diagnosis and treatment and medication safety of the vast number of users.

Based on its self-developed Cloudr Brain, the Company, as China's largest digital chronic condition management solution provider and a leading enterprise in AI-based healthcare, has taken the lead in formulating the technical framework, standards, requirements and data elements for system establishment in the consensus, with professional capabilities in technical research and development, data processing and artificial intelligence analysis and processing.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
ClouDr Group Limited

Chairman, Executive Director and Chief Executive Officer
Kuang Ming

Hong Kong, 12 June 2023

As at the date of this announcement, the Board comprises Mr. Kuang Ming as the executive Director, Mr. Lee Kar Chung Felix as the non-executive Director, and Dr. Hong Weili, Mr. Zhang Saiyin and Mr. Ang Khai Meng as the independent non-executive Directors.

* *For identification purpose only*